Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test different doses of X4P-001 given alone and in combination
with axitinib in patients diagnosed with advanced renal cell carcinoma. The goals of the
study are to determine the safety and tolerability of X4P-001, as well as the potential
effect it may have on the body and the cancer tumor.